5566-48-3

Basic information

• Product Name: 5-AMINO-6-CHLOROISOINDOLINE-1,3-DIONE
• Synonyms: 5-AMINO-6-CHLOROISOINDOLINE-1,3-DIONE;5-aMino-6-chloro-2,3-dihydro-1H-isoindole-1,3- dione;1H-Isoindole-1,3(2H)-dione,5-amino-6-chloro-
• CAS NO: 5566-48-3
• Molecular Formula: C8H5ClN2O2
• Molecular Weight: 196.5905
• Mol File: 5566-48-3.mol
• Article Data: 2

Chemical Properties

• Appearance: /
• Density: 1.614 g/cm³
• CAS DataBase Reference: 5-AMINO-6-CHLOROISOINDOLINE-1,3-DIONE(CAS DataBase Reference)
• NIST Chemistry Reference: 5-AMINO-6-CHLOROISOINDOLINE-1,3-DIONE(5566-48-3)
• EPA Substance Registry System: 5-AMINO-6-CHLOROISOINDOLINE-1,3-DIONE(5566-48-3)

Safety Data

• Hazardous Substances Data: 5566-48-3(Hazardous Substances Data)

Upstream product

• 89-20-3 4-chlorophthalic acid 
• 50-84-0 2,4 dichlorobenzoic acid 
• 7147-90-2 4-chlorophthalimide 
• 6015-57-2 5-chloro-6-nitroisoindole-1,3-dione 

Downstream Products

• 100448-44-0 7-Chloro-1-oxo-2-(3-trifluoromethyl-phenyl)-1,2,3,4-tetrahydro-phthalazine-6-sulfonic acid amide 
• 100448-34-8 7-Chloro-1-oxo-2-(3-trifluoromethyl-phenyl)-1,2-dihydro-phthalazine-6-sulfonic acid amide 
• 100448-54-2 7-Chloro-1-oxo-2-(3-trifluoromethyl-phenyl)-1,2-dihydro-phthalazine-6-sulfonyl chloride 
• 100448-43-9 2-Benzyl-7-chloro-1-oxo-1,2,3,4-tetrahydro-phthalazine-6-sulfonic acid amide 
• 100448-35-9 2-methyl-7-(phenylthio)-6-sulfamoyl-1(2H)-phthalazinone 
• 100448-58-6 2-(aminocarbonyl)-4-chloro-5-aminobenzaldehyde hydrazone 
• 100448-33-7 2-Benzyl-7-chloro-1-oxo-1,2-dihydro-phthalazine-6-sulfonic acid amide 
• 100448-53-1 2-Benzyl-7-chloro-1-oxo-1,2-dihydro-phthalazine-6-sulfonyl chloride 
• 100448-50-8 6-amino-7-chloro-2--1-(2H)-phthalazinone 
• 100448-49-5 6-amino-2-benzyl-7-chloro-1(2H)-phthalazinone 
• 100448-47-3 6-amino-7-chloro-1(2H)-phthalazinone 

Relevant articles and documents

ADAMTS INHIBITORS, PREPARATION METHODS AND MEDICINAL USES THEREOF

Compounds of formula (I) useful as inhibitors of ADAMTS-5 and/or ADAMTS-4, pharmaceutical compositions thereof, and use of them as therapeutic agents for the treatment of diseases involving degradation of cartilage or disruption of cartilage homeostasis, in particular osteoarthrosis and/or rheumatoid arthritis, are disclosed.